KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Long-Term Deferred Tax (2018 - 2019)

Historic Long-Term Deferred Tax for Novavax (NVAX) over the last 2 years, with Q4 2019 value amounting to $2.5 million.

  • Novavax's Long-Term Deferred Tax fell 2095.66% to $2.5 million in Q4 2019 from the same period last year, while for Dec 2019 it was $2.5 million, marking a year-over-year decrease of 2095.66%. This contributed to the annual value of $2.5 million for FY2019, which is 2095.66% down from last year.
  • Latest data reveals that Novavax reported Long-Term Deferred Tax of $2.5 million as of Q4 2019, which was down 2095.66% from $3.2 million recorded in Q4 2018.
  • In the past 5 years, Novavax's Long-Term Deferred Tax registered a high of $3.2 million during Q4 2018, and its lowest value of $2.5 million during Q4 2019.